US Patent 6,194,445: What Is Claimed, What the Scope Covers, and Where It Sits in the Landscape
US Patent 6,194,445 claims a dose-ranging method of treatment for restless legs syndrome (RLS) using a specific pramipexole species, with explicit dose limits and specific salt/enantiomer coverage.
What does claim 1 cover at the compound and dosing level?
Claim 1 is a method claim. It requires all of the following elements:
-
Therapeutic indication
- “treating restless legs syndrome” or treating “a patient suffering from such condition”
-
Drug identity (active form is restricted to pramipexole-family members in enumerated forms)
The claim covers administration of an “effective amount of”:
- 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole (the base compound)
- its (−)-enantiomer
- its dihydrochloride
- its dihydrochloride-(H2O) (hydratescope stated as dihydrochloride with water)
-
Dose range (hard numeric limitation)
- “where the dose of Pramipexole is about 0.001-10.0 mg/day”
-
Administration concept (method of treatment)
- “comprising the administration” of the effective amount within the claimed dosing window.
Practical claim construction (business-relevant): the claim is not limited to a particular formulation technology, route, or schedule in the excerpt you provided; it is anchored on (i) RLS, (ii) pramipexole identity in listed forms, and (iii) daily dose range.
How broad is the indication and patient class?
The indication is RLS (restless legs syndrome). The claim text you provided does not add extra sub-criteria (for example, severity grading, refractory status, or demographic limitations). That makes the patient class broad within RLS as a clinical diagnosis.
How broad is the chemical scope?
The claim’s chemical scope is restricted to pramipexole (and the base naming used in the claim), its (−)-enantiomer, and specific salt/hydrate forms:
- base compound
- (−)-enantiomer
- dihydrochloride
- dihydrochloride hydrate “(H2O)”
It does not (on the language you provided) enumerate:
- other hydrates (e.g., dihydrochloride monohydrate vs. other stoichiometries)
- alternate salts (e.g., sulfate, hydrochloride monohydrate)
- other enantiomers beyond “(−)-enantiomer”
How broad is the dosing scope?
The dose is a wide daily range: 0.001 to 10.0 mg/day.
That range has two key legal implications for landscape mapping:
- Competitor carve-outs are harder if they fall inside the range. If a competitor’s RLS regimen fits within 0.001-10 mg/day, it falls within the numeric limitation.
- Outside-range regimens may avoid the literal claim. If a regimen uses a daily dose above 10 mg/day or below 0.001 mg/day, literal infringement under claim 1 becomes harder to assert.
The claim uses “about,” which typically gives some leeway around exact boundary values, but the boundaries remain central for non-infringement and design-around analysis.
What is the claim’s scope in infringement terms?
Does the claim require a specific dosage regimen (schedule) or formulation?
Based on claim 1 text provided, the only hard parameters are:
- RLS indication
- pramipexole identity in listed forms
- daily dose within 0.001-10.0 mg/day
The excerpt does not add:
- specific routes (oral vs. other)
- titration schedule
- frequency (once daily vs. multiple daily doses)
- mg-per-dose vs. mg-per-day conversion rules
So, the scope is primarily indication + active form + daily dose.
How does the enumeration of salts and hydrates affect design-around?
If a generic or originator uses pramipexole in a form not enumerated (for example, a different hydrate form, different stoichiometry, or a different salt), that may affect literal scope. In practice, many products use dihydrochloride in one hydrate form, but a design-around may focus on form not listed in the claim. The claim excerpt you provided is explicit that dihydrochloride-(H2O) is included; it is not clear from your excerpt whether other hydrates are included.
Where does US 6,194,445 sit in the pramipexole/RLS patent landscape?
Landscape anchor: the core subject matter is RLS dosing with pramipexole
US 6,194,445 is tightly focused: it is not claiming a new chemical entity outside pramipexole. It is claiming use for RLS at a specified daily dose range using defined pramipexole forms.
In a typical pramipexole landscape, this type of claim tends to overlap with:
- earlier chemical composition patents covering pramipexole itself and salts
- later method-of-use patents covering treatment of neurologic disorders
- dosage regimen patents that add titration, frequency, or extended release formulations
- formulation patents (controlled release, specific polymorphs, processing)
Your provided claim 1 is the critical “use and dose window” component.
Claim strategy implications for generics
For a generic entrant seeking to position around this patent, the actionable levers are:
- dose placement: use a daily dose outside 0.001-10 mg/day (or design around the “about” concept)
- indication: avoid the RLS label and only market for other approved indications (if legally possible)
- product form: use a pramipexole form not within “2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole,” its (−)-enantiomer, dihydrochloride, or dihydrochloride-(H2O)
Because claim 1 is an RLS method claim, labeling and marketed indication become central to enforcement risk. Even if the drug is the same, using the claim as written typically targets medical use for RLS within the dose range.
Originator strategy implications
The originator (or assignee at the time) can use the numeric claim to argue that:
- RLS prescriptions falling within 0.001-10 mg/day infringe
- pramipexole forms in the enumerated list meet the compound element
The key weakness of this type of claim is that it is only as enforceable as its validity and as narrow as its numeric and enumerated chemical constraints.
Scope map: Claim 1 elements to real-world coverage
Coverage matrix
| Element in claim 1 |
What it requires |
Coverage impact |
| Indication |
Restless legs syndrome |
Broad for any patient diagnosed with RLS |
| Active species |
base compound, (−)-enantiomer, dihydrochloride, dihydrochloride-(H2O) |
Limits to enumerated pramipexole forms |
| Administration |
“comprising the administration” |
Encompasses treatment use, not just dosing research |
| Dose |
pramipexole about 0.001-10.0 mg/day |
Numeric gate for infringement risk |
Design-around levers (litigation-relevant)
- Indication design-around: market and prescribe for non-RLS uses (if legally permitted for the product)
- Dose design-around: daily dose outside 0.001-10 mg/day (with attention to “about”)
- Form design-around: pramipexole in a form not listed (other salt/hydrate/polymorph routes)
What evidence exists in the claim text for claim scope boundaries?
Hard boundaries
- Dose window is explicit: 0.001-10.0 mg/day
- Pramipexole forms are explicitly listed: base, (−)-enantiomer, dihydrochloride, dihydrochloride-(H2O)
- Indication is explicit: RLS
Soft boundaries (interpretation risk)
- “about” around the dose range
- what counts as “pramipexole” when using different salt forms and whether “effective amount” interacts with the mg/day boundary in litigation
Key takeaways
- US 6,194,445 claim 1 is a method-of-treatment claim for RLS requiring administration of pramipexole (as enumerated base/enantiomer/salt/hydrate) at about 0.001-10.0 mg/day.
- Scope is controlled by three gates: RLS diagnosis, listed pramipexole forms, and the daily dose range.
- Landscape positioning: the patent is best viewed as a RLS use-and-dose window within the broader pramipexole family (composition and salt/enantiomer patents typically cover the chemistry, while this focuses on treatment use and dosing).
- Design-around risk points for generics: staying out of RLS labeling/medical use, keeping daily dosing outside the claimed range, or using a pramipexole form not enumerated in the claim.
FAQs
1) Is US 6,194,445 a composition patent or a method-of-use patent?
It is a method for treating restless legs syndrome, not a composition claim, as reflected in claim 1’s “method for treating” structure.
2) Does the claim cover only one enantiomer?
Yes. Claim 1 enumerates pramipexole and its (−)-enantiomer.
3) What pramipexole forms are explicitly included?
The claim includes 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole, its (−)-enantiomer, dihydrochloride, and dihydrochloride-(H2O).
4) What is the claimed daily dose range?
Claim 1 recites a pramipexole daily dose “about 0.001-10.0 mg/day.”
5) What is the strongest infringement hook?
For RLS prescriptions within 0.001-10.0 mg/day using a covered pramipexole form, the claim’s combination of indication + drug form + numeric dose creates a direct enforcement pathway.
References (APA)
[1] U.S. Patent 6,194,445.
